-
UNPARALLELED SCALABILITY
10x increase in productivity compared with conventional CDMOs
-
COST SAVINGS
50% lower price per batch compared with conventional CDMOs
-
QUALITY
75% lower process failure rates compared with conventional CDMOs
-
Smart Factory
South San Francisco, CA - Preclinical & Clinical Services / Technology Development
- 57,000 Sq Ft
-
Smart Factory
South San Francisco, CA - Preclinical & Clinical Services / Technology Development
- 57,000 Sq Ft
-
Smart Factory
Bridgewater, NJ - Preclinical, Clinical & Commercial Services
- 118,000 Sq Ft
-
Smart Factory
Bridgewater, NJ - Preclinical, Clinical & Commercial Services
- 118,000 Sq Ft
-
Smart Factory - Europe
COMING SOON - Preclinical, Clinical & Commercial Services
-
Smart Factory - Europe
COMING SOON - Preclinical, Clinical & Commercial Services
-
Smart Factory - Asia
COMING SOON - Preclinical, Clinical & Commercial Services
-
Smart Factory - Asia
COMING SOON - Preclinical, Clinical & Commercial Services
- Existing Smart Factories
- Planned Smart Factories
- Manufacturing Services
-
- Advanced Technology
Technology
Powered by Advanced Cell Therapy Manufacturing Technologies
Technology
Powered by Advanced Cell Therapy Manufacturing Technologies
Consumable Cartridge
True end-to-end automation in a closed and automated single-use cartridge
-
Scalability
10x increase in productivity
-
Cost Savings
50% reduction in cost per batch
-
QUALITY
75% reduction in process failure rates
-
FLEXIBILITY
90% of cell therapy modalities supported
Careers
Do What’s Never Been Done Before
Cellares is always looking for passionate and world-class professionals to join our interdisciplinary team
-
October 10, 2023
Exclusive: Cellares expands deal with Bristol Myers on preclinical CAR-T asset, eyes manufacturing expansion
-
September 11, 2023
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell’s CAR T-Cell Therapy on Cellares’ Cell Shuttle Platform
-
August 28, 2023
Cellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program to Evaluate Automated Manufacturing of CAR-T Cell Therapy on the Cell Shuttle Platform
